Primary Treatment: 1726nm Laser Treatment · Has Placebo Group · N/A
1726nm Laser Treatment
Experimental Group · 1 Intervention: 1726nm Laser System · Intervention Types: Device
Sham Laser Treatment
ShamComparator Group · 1 Intervention: Sham Laser System · Intervention Types: Device
Screening: ~3 weeks
Reporting: 12 week follow-up
Closest Location: Alberta DermaSurgery Centre · Edmonton, Canada
2019First Recorded Clinical Trial
0 TrialsResearching Acne
5 CompletedClinical Trials
Age < 65 · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a skin type of I-VI.
You have ≥ 15 inflammatory acne lesions on the full face as determined by the Investigator (or qualified designee).
You must be able to read, speak, and understand English and sign the Informed Consent Form.
You are willing to stop using topical acne medications on the face for 2 weeks prior to baseline and systemic acne medications for 1 month prior to baseline and for the duration of the study.
You are willing and able to comply with the treatment and follow-up schedule and pre/post-treatment care instructions.
You have clinically diagnosed acne vulgaris of severity grade 3 - 4 (moderate to severe) on each hemiface as determined by the blinded trained investigator (or qualified designee) using the Investigator's Global Assessment Scale.
You are willing to be in the sun for a limited amount of time every day, and use an approved sunscreen or sunscreen with SPF (Skin Protection Factor) 30 or higher
You are willing to have photographs taken of your face and agree to the use of photographs for presentation, educational or marketing purposes.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.